Showing 391-400 of 7495 results for "".
2014 Year in Review: Innovation in Laser & Light
https://practicaldermatology.com/topics/practice-management/2014-year-in-review-innovation-in-laser-light--iledirim/19004/R. Rox Anderson, MD reflects on the meaning of innovation and discusses why dermatology as a specialty is home to many important advances in the field of laser and light therapy.The Big Idea: Jeanine Downie, MD on Purchasing Her Own Space
https://practicaldermatology.com/topics/practice-management/the-big-idea-jeanine-downie-md-on-purchasing-her-own-space/19278/Dr. Downie explains why she wanted her own space and describes the major and minor benefits of ownership, including cost savings. Featured in "What's The Big Idea"BodyJet Irrigation Liposuction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/bodyjet_meyer-irrigation/19519/Demonstration of proper technique for water-assisted liposuction, including placement of cannula and fat extraction.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Journal Club: AD's Impact on Mental Health
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-ads-impact-mental-health/28628/Practical Dermatology Editorial Board member Peter Lio, MD, chats with dermatologist Robert Sidbury, MD, MPH, about the Cureus article, "Investigation of the Impact of Atopic Dermatitis (AD) on Stress, Depression, Anxiety, and Suicidal Ideation: A Systematic Review and Meta-Analysis."ISDPA: Dr. Lio on Alternative and Innovative Approaches
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-lio-alternative-and-innovative-approaches/27066/Practical Dermatology Editorial Board member Peter Lio, MD, discusses the presentation that he and Tracee Blackburn, PA-C, gave about alternative and innovative approaches in dermatology, as well as the importance of educational engagement between physician assistants and dermatologists, at the IlliASLMS New Beginnings Initiative
https://practicaldermatology.com/programs/practical-dermatology/aslms-new-beginnings-initiative/18188/In 2014, the American Society for Laser Medicine and Surgery started its New Beginnings initiative. Initially launched to benefit cancer survivors, ASLMS physicians volunteered to remove radiation tattoos pro bono. Recently, the ASLMS, under the leadership of its president Paul Friedman, MD, expandeDermWireTV: Diversity in Dermatology; Inclusive Beauty Initiatives; Eczema Awareness Month
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-diversity-in-dermatology-inclusive-beauty-initiatives-eczema-awareness-month/20152/La Roche-Posay and the Women's Dermatologic Society have partnered to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for Underrepresented in medicine medical students. WDS President Mona Gohara, MD shares insights about the need to support DEI in derScientifically Speaking: Rox Anderson, MD Talks Changing Lives Through Inventions
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-rox-anderson-md-talks-changing-lives-through-inventions/20140/Rox Anderson, MD has been at the forefront of inventions that have shaped the modern practice of dermatology. He discusses his inspirations and his desire to advance patient care. Host Joel L. Cohen, MD talks to him about his latest innovations and a recent recognition.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.